ANNX Annexon

Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference

Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference

BRISBANE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023 at 1:30 p.m. ET.

A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon

Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company seeking to bring game-changing medicines to patients with classical complement-mediated diseases of the body, brain and eye. The classical complement cascade is a seminal pathway within the immune system that anchors and drives a host of autoimmune, neurodegenerative and ophthalmic diseases. Annexon is advancing a new class of complement medicines targeting the early classical cascade and all downstream pathway components that contribute to disease, while selectively preserving the beneficial immune functions of other complement pathways. Annexon is rigorously developing a pipeline of diversified product candidates across multiple mid- to late-stage clinical trials, with clinical data anticipated throughout 2023 and beyond.

Investor Contact:

Chelcie Lister

THRUST Strategic Communications

Media Contact:

Sheryl Seapy

Real Chemistry

949-903-4750



EN
11/04/2023

Underlying

ANNXAnnexon

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Annexon

 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care...

Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president and chief executive officer, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 9:50 a.m. ET. A live webcast of the event can be accessed under the ‘Events & ...

February 24, 2026 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument...

Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy BRISBANE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it will host an in-person and virtual key opinion leader (KOL) event in New York on Wednesday, March 18, 2026, with presentations at 2:00 PM ET and a reception at 4:00 PM ET. To register, . The event w...

February 17, 2026 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listin...

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on January 9, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4)....

January 16, 2026 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Accelerating Next Generation Targeted Immunotherapy Platform f...

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal Phase 3 Topline Data for Dry AMD with Geographic Atrophy (GA) on Track for Second Half of 2026 Evaluating Unprecedented Effect on Vision Protection Proof-of-Concept Data for ANX1502, the First Oral C1 Inhibitor for Autoimmune Disease, Expect...

January 12, 2026 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Submits Tanruprubart Marketing Authorization Application to th...

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026 BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced it has submitted a Marketing Auth...

January 8, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch